SG11201500134QA - Composition comprising a mixture of cd95-fc isoforms - Google Patents

Composition comprising a mixture of cd95-fc isoforms

Info

Publication number
SG11201500134QA
SG11201500134QA SG11201500134QA SG11201500134QA SG11201500134QA SG 11201500134Q A SG11201500134Q A SG 11201500134QA SG 11201500134Q A SG11201500134Q A SG 11201500134QA SG 11201500134Q A SG11201500134Q A SG 11201500134QA SG 11201500134Q A SG11201500134Q A SG 11201500134QA
Authority
SG
Singapore
Prior art keywords
isoforms
mixture
composition
Prior art date
Application number
SG11201500134QA
Other languages
English (en)
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Original Assignee
Apogenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh filed Critical Apogenix Gmbh
Publication of SG11201500134QA publication Critical patent/SG11201500134QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
SG11201500134QA 2012-07-18 2013-07-18 Composition comprising a mixture of cd95-fc isoforms SG11201500134QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12176980 2012-07-18
EP12176978 2012-07-18
PCT/EP2013/065250 WO2014013039A1 (en) 2012-07-18 2013-07-18 Composition comprising a mixture of cd95-fc isoforms

Publications (1)

Publication Number Publication Date
SG11201500134QA true SG11201500134QA (en) 2015-03-30

Family

ID=48794121

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500134QA SG11201500134QA (en) 2012-07-18 2013-07-18 Composition comprising a mixture of cd95-fc isoforms

Country Status (18)

Country Link
US (5) US9315570B2 (enrdf_load_stackoverflow)
EP (4) EP3406630B1 (enrdf_load_stackoverflow)
JP (2) JP6231562B2 (enrdf_load_stackoverflow)
KR (1) KR102201694B1 (enrdf_load_stackoverflow)
CN (3) CN104662039B (enrdf_load_stackoverflow)
AU (2) AU2013291984B2 (enrdf_load_stackoverflow)
BR (1) BR112015000732B1 (enrdf_load_stackoverflow)
CA (2) CA2877989C (enrdf_load_stackoverflow)
DK (2) DK3409686T3 (enrdf_load_stackoverflow)
ES (2) ES2924109T3 (enrdf_load_stackoverflow)
HK (1) HK1207095A1 (enrdf_load_stackoverflow)
IL (1) IL236659A (enrdf_load_stackoverflow)
MX (1) MX371430B (enrdf_load_stackoverflow)
NZ (1) NZ703546A (enrdf_load_stackoverflow)
RU (2) RU2648146C2 (enrdf_load_stackoverflow)
SG (1) SG11201500134QA (enrdf_load_stackoverflow)
UA (1) UA116889C2 (enrdf_load_stackoverflow)
WO (2) WO2014013037A1 (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015000732B1 (pt) * 2012-07-18 2023-01-10 Apogenix Ag Composição farmacêutica compreendendo uma mistura de isoformas de cd95-fc, método para a produção da mesma e formulação
AU2014261505B2 (en) * 2013-04-29 2019-04-18 Apogenix Ag Method of diagnosing cancer
NO2776305T3 (enrdf_load_stackoverflow) * 2014-04-23 2018-01-27
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
US9587215B2 (en) 2014-08-07 2017-03-07 General Electric Company Devices, systems and methods for automated transfer of a sample
JP6783767B2 (ja) * 2014-12-22 2020-11-11 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 組換えタンパク質を精製する方法
CN114269370A (zh) 2019-03-29 2022-04-01 迈斯特治疗公司 离体产生t细胞治疗剂的方法以及相关的组合物和方法
KR20220122639A (ko) 2019-11-27 2022-09-02 미스트 쎄라퓨틱스, 엘엘씨 조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법
JP7737374B2 (ja) * 2019-12-12 2025-09-10 イー・エム・デイー・ミリポア・コーポレイシヨン 透析濾過緩衝液を用いて増強したウイルス濾過
EP4512828A3 (en) 2020-02-27 2025-05-14 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
CN115894706A (zh) * 2021-09-30 2023-04-04 北京康辰药业股份有限公司 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2253494A1 (en) * 1996-05-02 1997-11-13 Mochida Pharmaceutical Co., Ltd. Novel fas antigen derivative
ATE273713T1 (de) * 1996-10-31 2004-09-15 Mochida Pharm Co Ltd Fas-antagonist für die prophylaxe oder therapie von gvhd
WO1998038304A1 (fr) * 1997-02-27 1998-09-03 Ono Pharmaceutical Co., Ltd. Nouveau polypeptide, adn le codant et utilisation de ce polypeptide
US6905684B1 (en) * 1997-11-10 2005-06-14 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung diseases
CN1911965B (zh) * 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
EP1273297A1 (en) * 2001-07-06 2003-01-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction)
ES2327409T3 (es) * 2003-03-26 2009-10-29 Apogenix Gmbh Proteinas de fusion fc mejoradas.
EP2004216A4 (en) * 2006-03-28 2012-02-01 Molecular Discovery Systems AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF
ES2371287T3 (es) * 2006-06-21 2011-12-29 Apogenix Gmbh Expresión diferencial de la citocina en cáncer humano.
AU2007341631B9 (en) * 2006-12-28 2012-10-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
WO2008101671A2 (en) * 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
EP2310409A2 (en) 2008-06-17 2011-04-20 Apogenix GmbH Multimeric tnf receptors
ES2593049T3 (es) * 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
EP2456468A1 (en) * 2009-07-21 2012-05-30 Queen Mary and Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
RU2012127383A (ru) * 2009-12-02 2014-01-10 Акселерон Фарма Инк. Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке
BR112015000732B1 (pt) * 2012-07-18 2023-01-10 Apogenix Ag Composição farmacêutica compreendendo uma mistura de isoformas de cd95-fc, método para a produção da mesma e formulação
AU2014261505B2 (en) * 2013-04-29 2019-04-18 Apogenix Ag Method of diagnosing cancer

Also Published As

Publication number Publication date
KR102201694B1 (ko) 2021-01-12
DK2875045T3 (en) 2018-07-02
WO2014013037A1 (en) 2014-01-23
EP3409686B1 (en) 2022-04-13
US20150166633A1 (en) 2015-06-18
ES2674662T3 (es) 2018-07-03
EP2875045A1 (en) 2015-05-27
HK1207095A1 (en) 2016-01-22
US9908928B2 (en) 2018-03-06
AU2013291982A1 (en) 2015-02-05
US20160235815A1 (en) 2016-08-18
EP3406630B1 (en) 2020-09-02
EP2875044A1 (en) 2015-05-27
CN104662039B (zh) 2019-10-08
US9315570B2 (en) 2016-04-19
EP2875045B1 (en) 2018-03-28
CA2878992A1 (en) 2014-01-23
BR112015000732B1 (pt) 2023-01-10
US10370441B2 (en) 2019-08-06
RU2015105328A (ru) 2016-09-10
AU2013291984B2 (en) 2018-01-18
US9434783B2 (en) 2016-09-06
CA2878992C (en) 2020-09-22
MX371430B (es) 2020-01-30
RU2015105330A (ru) 2016-09-10
AU2013291982B2 (en) 2017-01-12
EP3409686A1 (en) 2018-12-05
AU2013291984A1 (en) 2015-02-05
CN104640876A (zh) 2015-05-20
CA2877989A1 (en) 2014-01-23
KR20150048120A (ko) 2015-05-06
RU2648146C2 (ru) 2018-03-22
CA2877989C (en) 2021-05-25
JP2015528006A (ja) 2015-09-24
CN104662039A (zh) 2015-05-27
WO2014013039A1 (en) 2014-01-23
BR112015000732A2 (enrdf_load_stackoverflow) 2017-08-15
US20150225475A1 (en) 2015-08-13
US20180186856A1 (en) 2018-07-05
UA116889C2 (uk) 2018-05-25
CN109897115A (zh) 2019-06-18
US20160362471A1 (en) 2016-12-15
DK3409686T3 (da) 2022-07-18
JP6231562B2 (ja) 2017-11-15
JP6317739B2 (ja) 2018-04-25
HK1207096A1 (en) 2016-01-22
RU2648157C2 (ru) 2018-03-22
IL236659A0 (en) 2015-02-26
MX2015000731A (es) 2015-09-04
EP3406630A1 (en) 2018-11-28
EP2875044B1 (en) 2018-04-11
IL236659A (en) 2017-02-28
NZ703546A (en) 2018-03-23
JP2015524403A (ja) 2015-08-24
ES2924109T3 (es) 2022-10-04
US9657083B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
ZA201501847B (en) Formulations of enzalutamide
IL236659A (en) A preparation comprising a mixture of cd95 – fc isoforms
PL2855550T3 (pl) Poliuretanowe kompozycje zaprawowe
GB201217441D0 (en) Composition
GB201200707D0 (en) Composition
EP2878295A4 (en) COMPOSITION
GB201218954D0 (en) Composition
GB201501016D0 (en) Preparation of 18F-fluciclovine
IL238381B (en) Transdermal preparations based on propyleneaminoindan
EP2867199A4 (en) STABLE COMPOSITIONS OF ESOTRERODINE
GB201420971D0 (en) Therapeutic composition
GB201219657D0 (en) Composition
GB201206035D0 (en) Composition
ZA201402166B (en) Compositions of efavirenz
IL217807A0 (en) Therapeutic compositions
GB201218195D0 (en) Composition
GB201209597D0 (en) Composition
GB201218355D0 (en) Surfacing mixture
GB201219383D0 (en) Composition
GB201209895D0 (en) Use of a composition
GB201214237D0 (en) Novel therapeutic composition
SG11201401570YA (en) Pharmaceutical compositions of resveratrol
GB201221334D0 (en) Composition
GB201220838D0 (en) Composition
GB201219065D0 (en) Composition